| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Fovioptics (Main) is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a dynamic organization committed to providing compassionate, high-quality healthcare across the Northern California East Bay.
OrphoMed is a San Francisco based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents.
Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.